Ensol Biosciences Inc. (XKON: 140610)
6,220.00
-240.00 (-3.72%)
Sep 10, 2024, 9:00 AM KST
Ensol Biosciences Balance Sheet
Financials in millions KRW. Fiscal year is January - December.
Millions KRW. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2017 | FY 2016 | FY 2015 |
---|---|---|---|---|
Period Ending | Dec '17 Dec 31, 2017 | Dec '17 Dec 31, 2017 | Dec '16 Dec 31, 2016 | Dec '15 Dec 31, 2015 |
Cash & Equivalents | 721.34 | 721.34 | 2,921 | 6,064 |
Short-Term Investments | 1,901 | 1,901 | 4,159 | 1,501 |
Cash & Short-Term Investments | 2,622 | 2,622 | 7,080 | 7,565 |
Cash Growth | - | -62.96% | -6.42% | - |
Accounts Receivable | 48.61 | 48.61 | - | 26.28 |
Other Receivables | 5.73 | 5.73 | 40.11 | 7.71 |
Receivables | 104.34 | 104.34 | 40.11 | 33.99 |
Prepaid Expenses | 36.4 | 36.4 | 70.03 | 27.59 |
Other Current Assets | 87.19 | 87.19 | 106.49 | 82 |
Total Current Assets | 2,850 | 2,850 | 7,297 | 7,709 |
Property, Plant & Equipment | 4,249 | 4,249 | 4,447 | 4,636 |
Long-Term Investments | - | - | - | 0 |
Other Intangible Assets | 128.12 | 128.12 | 104.58 | 127.59 |
Long-Term Deferred Charges | - | - | 266.16 | 126.5 |
Other Long-Term Assets | 393.9 | 393.9 | 747.7 | 406.63 |
Total Assets | 7,621 | 7,621 | 12,912 | 13,056 |
Accrued Expenses | 202.38 | 202.38 | 100.62 | 89.1 |
Short-Term Debt | 30 | 30 | - | 1,680 |
Current Portion of Long-Term Debt | - | - | - | 180 |
Other Current Liabilities | 83.99 | 83.99 | 467.63 | 84.47 |
Total Current Liabilities | 316.36 | 316.36 | 568.25 | 2,034 |
Other Long-Term Liabilities | 32.5 | 32.5 | 24.13 | 61.57 |
Total Liabilities | 1,057 | 1,057 | 1,202 | 2,581 |
Common Stock | 4,198 | 4,198 | 4,198 | 2,021 |
Additional Paid-In Capital | 31,149 | 31,149 | 31,149 | 26,340 |
Retained Earnings | -29,453 | -29,453 | -24,032 | -17,934 |
Comprensive Income & Other | 670.39 | 670.39 | 395.47 | 47.76 |
Shareholders' Equity | 6,564 | 6,564 | 11,710 | 10,475 |
Total Liabilities & Equity | 7,621 | 7,621 | 12,912 | 13,056 |
Total Debt | 30 | 30 | - | 1,860 |
Net Cash (Debt) | 2,592 | 2,592 | 7,080 | 5,705 |
Net Cash Growth | - | -63.39% | 24.09% | - |
Net Cash Per Share | 308.93 | 308.93 | 858.84 | 849.11 |
Filing Date Shares Outstanding | 8.39 | 8.39 | 8.24 | 6.72 |
Total Common Shares Outstanding | 8.39 | 8.39 | 8.24 | 6.72 |
Working Capital | 2,534 | 2,534 | 6,728 | 5,675 |
Book Value Per Share | 782.26 | 782.26 | 1420.48 | 1558.92 |
Tangible Book Value | 6,436 | 6,436 | 11,605 | 10,347 |
Tangible Book Value Per Share | 767.00 | 767.00 | 1407.79 | 1539.93 |
Land | 615.31 | 615.31 | 615.31 | 615.31 |
Buildings | 3,582 | 3,582 | 3,582 | 3,582 |
Machinery | 642.34 | 642.34 | 538.96 | 428.76 |
Source: S&P Capital IQ. Standard template. Financial Sources.